Prognosis in HR-positive metastatic breast cancer with HER2-low versus HER2-zero treated with CDK4/6 inhibitor and endocrine therapy: a meta-analysis.

Front Oncol · 2024 · PMC11390584 · PMID 39267829

Europe PMC DOI

hedged sentence

0.4770

closest p · 9.5× alpha

0.4770

boldest claim

The sentences

did not reach statistical significanceP =0.477not close (p > 0.1)

2+), but this difference did not reach statistical significance ( P =0.477) ( 28 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.